Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death Protein 1 Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06835179
What this trial is testing

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Who this might be right for
Unresectable Metastatic Colorectal CancerMicrosatellite Stable (MSS) Colorectal Cancer (CRC)RAS-mutant Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University 28
Testing effectiveness (Phase 2)UnknownNCT03171220
What this trial is testing

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Who this might be right for
Advanced Malignant Solid Tumor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 40
Testing effectiveness (Phase 2)Looking for participantsNCT05758389
What this trial is testing

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Who this might be right for
Head and Neck Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 29
Early research (Phase 1)UnknownNCT04193098
What this trial is testing

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerSecond-line Treatment
Tianjin Medical University Cancer Institute and Hospital 10
Not applicableActive Not RecruitingNCT06865521
What this trial is testing

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

Who this might be right for
Colo-rectal CancerPD-1 InhibitorAkkermansia Muciniphila
West China Hospital 22
Not applicableLooking for participantsNCT06549855
What this trial is testing

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Who this might be right for
Endometrial CancerEndometrioid CarcinomaMismatch Repair Deficiency
Peking University People's Hospital 10
Not applicableUnknownNCT05032014
What this trial is testing

Probiotics Enhance the Treatment of PD-1 Inhibitors in Patients With Liver Cancer

Who this might be right for
Liver Cancer
Jiangxi Provincial Cancer Hospital 46
Testing effectiveness (Phase 2)UnknownNCT06304987
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 50
Testing effectiveness (Phase 2)UnknownNCT04681287
What this trial is testing

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Henan Cancer Hospital 46
Early research (Phase 1)WithdrawnNCT05472506
What this trial is testing

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Who this might be right for
Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead Cancer+3 more
Ikena Oncology
Not applicableNot Yet RecruitingNCT07350824
What this trial is testing

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Who this might be right for
HCCMinimal Residual DiseaseRecurrence
Tongji Hospital 276
Testing effectiveness (Phase 2)UnknownNCT05520853
What this trial is testing

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Who this might be right for
Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC
First People's Hospital of Hangzhou 63
Early research (Phase 1)Looking for participantsNCT07285395
What this trial is testing

AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

Who this might be right for
Advanced Solid Tumors
The Affiliated Hospital of Xuzhou Medical University 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04139902
What this trial is testing

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Diwakar Davar 48
Testing effectiveness (Phase 2)UnknownNCT06156878
What this trial is testing

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Who this might be right for
Nasopharyngeal Carcinoma
Fudan University 41
Very early researchActive Not RecruitingNCT04134325
What this trial is testing

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Who this might be right for
Relapsed Hodgkin LymphomaRefractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)UnknownNCT04624984
What this trial is testing

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Who this might be right for
Classical Hodgkin LymphomaRefractory or Relapsed Classical Hodgkin Lymphoma
Sun Yat-sen University 42
Testing effectiveness (Phase 2)Study completedNCT05162352
What this trial is testing

Donafenib Plus Sintilimab for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 30
Early research (Phase 1)Study completedNCT02298946
What this trial is testing

AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerColorectal NeoplasmsColorectal Carcinoma
National Cancer Institute (NCI) 17
Large-scale testing (Phase 3)Looking for participantsNCT06190782
What this trial is testing

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Who this might be right for
Esophageal Squamous Cell CarcinomaOligometastatic DiseaseRadiotherapy
Fudan University 354
Next Page